Top

Published in:

01-07-2014 | Special Report

Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update

Authors: Yasuo Suzuki, Hajime Nawata, Satoshi Soen, Saeko Fujiwara, Hisanori Nakayama, Ikuko Tanaka, Keiichi Ozono, Akira Sagawa, Ryoichi Takayanagi, Hiroyuki Tanaka, Takami Miki, Naomi Masunari, Yoshiya Tanaka

Published in: Journal of Bone and Mineral Metabolism | Issue 4/2014

Excerpt

Glucocorticoids (GCs) are widely used to treat various inflammatory, immunologic, and allergic disorders that cause rheumatic, respiratory, bowel, hepatic, neurological, renal, and skin diseases. Osteoporosis is the most common and important adverse effect of GC therapy, and fractures occur in 30–50 % of adult patients receiving long-term GC therapy [1, 2]. Glucocorticoid-induced osteoporosis (GIO) is the most common type of secondary osteoporosis, and it occurs in patients of all ages, from children to the elderly. …

Weinstein RS (2011) Glucocorticoid-induced bone disease. N Engl J Med 365:62–70PubMedCrossRef

Van Staa TP, Leukens HGM, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787PubMedCrossRef

LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, Tartarotti D, DellaRocca C (1990) Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39–51PubMedCrossRef

Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229PubMedCrossRef

American College of Rheumatology Task Force on Osteoporosis Guidelines (1996) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 39:1791–1801CrossRef

Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, Brown J, Cowden EA, Goltzman D, Ioannidis G, Josse RG, Ste-Marie LG, Tenenhouse AM, Davison KS, Blocka KL, Pollock AP, Sibley J (2000) Management of corticosteroid-induced osteoporosis. Sem Arthritis Rheum 29:228–251CrossRef

American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis 2001 update. Arthritis Rheum 44:1496–1503CrossRef

Royal College of Physicians (2002) Glucocorticoid-induced osteoporosis: Guidelines on Prevention and Treatment. Bone and Tooth Society of Great Britain. National Osteoporosis Society and Royal College of Physicians, London

Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M, Matsumoto T, Suzuki Y, Tanaka H, Fujiwara S, Miki T, Sagawa A, Nishizawa Y, Seino Y (2005) Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23:105–109PubMedCrossRef

10.

Kanis JA (2007) On behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield

11.

Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028–2039PubMedCrossRef

12.

Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60:3346–3355PubMedCrossRef

13.

Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 62:1515–1526CrossRef

14.

Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Diez Perez A, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257–2276PubMedCrossRef

15.

Kirigaya D, Nakayama T, Ishizaki T, Ikeda S, Satoh T (2011) Management and treatment of osteoporosis in patients receiving long-term glucocorticoid treatment: current status of adherence to clinical guidelines and related factors. Intern Med 50:2793–2800PubMedCrossRef

16.

Guzman-Clark JR, Fang MA, Sehl ME, Traylor L, Hahn TJ (2007) Barriers in the management of glucocorticoid-induced osteoporosis. Arthritis Rheum 57:140–146PubMedCrossRef

17.

Compston J (2011) Clinical question: what is the best approach to managing glucocorticoid-induced osteoporosis. Clin Endocrinol (Oxf) 74:547–550CrossRef

18.

The Ad Hoc Committee to develop Guidelines for Prevention and Treatment of Osteoporosis (The Japanese Society for Bone and Mineral Research/Japan Osteoporosis Society Collaborative Initiative.) (2011) Guidelines for Prevention and Treatment of Osteoporosis, 2011th edn. Life Science, Tokyo

19.

Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299PubMedCrossRef

20.

Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211PubMedCrossRef

21.

de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, Buskens E, de Laet CE, Oostveen AC, Geusens PP, Bruyn GA, Dijkmans BA, Bijlsma JW, STOP Investigators (2006) Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355:675–684PubMedCrossRef

22.

Stoch SA, Saag KG, Greenwald M, Sebba AI, Cohen S, Verbruggen N, Giezek H, West J, Schnitzer TJ (2009) Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 36:1705–1714PubMedCrossRef

23.

Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42:2309–2318PubMedCrossRef

24.

Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006–1013PubMedCrossRef

25.

Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 69:242–247PubMedCrossRef

26.

Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, Nagant de Deuxchaisnes C, Russell RG (2000) Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11:331–337PubMedCrossRef

27.

Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382–387PubMedCrossRef

28.

Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, Di Munno O, Pouillès JM, Horlait S, Cortet B (1998) Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 83:1128–1133PubMedCrossRef

29.

Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F (2003) Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from long-term comparative study. Osteoporos Int 14:801–807PubMedCrossRef

30.

Ringe JD, Dorst A, Faber H, Ibach K, Preuss J (2003) Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology 42:743–749PubMedCrossRef

31.

Hakala M, Kröger H, Valleala H, Hienonen-Kempas T, Lehtonen-Veromaa M, Heikkinen J, Tuomiranta T, Hannonen P, Paimela L, ONCE trial group (2012) Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind. Placebo-controlled trial. Scand J Rheumatol 41:260–266PubMedCrossRef

32.

Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, Obermayer-Pietsch BM, Pilz S, Dimai HP, Prenner G, Tscheliessnigg KH, Hauge E, Portugaller RH, Dobnig H (2009) Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 24:1335–1344PubMedCrossRef

33.

Reginster JY, Kuntz D, Verdickt W, Wouters M, Guillevin L, Menkès CJ, Nielsen K (1999) Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 9:75–81PubMedCrossRef

34.

Ringe JD, Cöster A, Meng T, Schacht E, Umbach R (1999) Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 65:337–340PubMedCrossRef

35.

Sambrook PN, Kotowicz M, Nash P, Styles CB, Naganathan V, Henderson-Briffa KN, Eisman JA, Nicholson GC (2003) Prevention and treatment of glucocorticoid-induced osteoporosis.: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 18:919–924PubMedCrossRef

36.

Amin S, Lavalley MP, Simms RW, Felson DT (2002) The comparative efficacy of drug therpies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 17:1512–1526PubMedCrossRef

37.

de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW (2004) Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 15:589–602PubMedCrossRef

38.

Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M, Krohn K, See K, Warner MR (2009) Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int 20:2095–2104PubMedCrossRef

39.

Devogelaer JP, Adler RA, Recknor C, See K, Warner MR, Wong M, Krohn K (2010) Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol 37:141–148PubMedCrossRef

40.

Karras D, Stoykov I, Lems WF, Langdahl BL, Ljunggren Ö, Barrett A, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Jakob F, Marin F (2012) Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study. J Rheumatol 39:600–609PubMedCrossRef

41.

Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129–2134PubMed

42.

Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479–1491PubMedCrossRef

43.

Urade M, Tanaka N, Furusawa K, Shimada J, Shibata T, Kirita T, Yamamoto T, Ikebe T, Kitagawa Y, Fukuta J (2011) Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg 69:e364–e371PubMedCrossRef

44.

Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Toyosawa S, Nagata T, Urade M (2010) Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and mineral Research, Japan Osteoporosis Society, Japanese Society for Oral and Maxillofacial Radiology and Japanese Society of Oral and Maxillofacila Surgeons. J Bone Miner Metab 28:365–383PubMedCrossRef

45.

Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294PubMedCrossRef

46.

Schilcher J, Michaëlsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737PubMedCrossRef

47.

Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1–23PubMedCrossRef

48.

Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, Moretti M, Koren G, Ito S (2009) Pregnancy outcome following in utero exposure to bisphosphonates. Bone 44:428–430PubMedCrossRef

49.

Ornoy A, Wajnberg R, Diav-Citrin O (2006) The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 22:578–579PubMedCrossRef

50.

Chan B, Zacharin M (2006) Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 91:2017–2020PubMedCrossRef

51.

Munns CF, Rauch F, Ward L, Glorieux FH (2004) Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19:1742–1745PubMedCrossRef

52.

Siminoski K, Fitzgerald AA, Flesch G, Gross MS (2000) Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding. J Bone Miner Res 15:2052–2055PubMedCrossRef

53.

MaNicholl DM, Heaney LG (2010) The safety of bisphosphonate use in premenopausal women on corticosteroids. Curr Drug Saf 5:182–187CrossRef

Title: Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update
Authors: Yasuo Suzuki
Hajime Nawata
Satoshi Soen
Saeko Fujiwara
Hisanori Nakayama
Ikuko Tanaka
Keiichi Ozono
Akira Sagawa
Ryoichi Takayanagi
Hiroyuki Tanaka
Takami Miki
Naomi Masunari
Yoshiya Tanaka
Publication date: 01-07-2014
Publisher: Springer Japan
Published in: Journal of Bone and Mineral Metabolism / Issue 4/2014
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-014-0586-6

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2014

Genetic basis of familial isolated hyperparathyroidism: a case series and a narrative review of the literature

Familial interactions and physical, lifestyle, and dietary factors to affect bone mineral density of children in the KNHANES 2009–2010

Millimeter wave promotes the synthesis of extracellular matrix and the proliferation of chondrocyte by regulating the voltage-gated K+ channel

Phosphate enhances reactive oxygen species production and suppresses osteoblastic differentiation

The benefits of a high-intensity aquatic exercise program (HydrOS) for bone metabolism and bone mass of postmenopausal women

High prevalence of spine–femur bone mineral density discordance and comparison of vertebral fracture risk assessment using femoral neck and lumbar spine bone density in Korean patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page